

The Biologics Prescribers Collaborative advocates for policies that improve access, confidence and safety for biologics and biosimilars.

Encouraging Sound Policy

The Biologics Prescribers Collaborative aims to ensure that sound policies are in place to promote the safest use of all biological medications for all patients.

The group has several core principles:

1. The patient-clinician relationship is critical and must remain intact.
2. Prescribers must be fully informed to understand the distinct therapeutic choices for their patients.
3. Patients deserve information about the medications they receive.

The principles are guided by an emphasis on patient safety and health.

Educating Prescribers & Patients

Given the organization's focus on informed decision-making, members work together to create and share educational materials. The Biologics Prescribers Collaborative also supports prescriber and patient education programs.

At a Glance



Innovator Biologics

are biological medications developed from living organisms, such microorganisms or tissue.



Biosimilars

are biological medications based on the innovator biologic. They have no clinically meaningful difference from the innovator.



Interchangeable Biosimilars

have undergone further testing and met additional requirements. They can be swapped for an innovator biologic without the prescribing clinician's involvement.



All biological medications are safe to use once approved by the FDA.

To learn more about BPC, contact leadership@biologicsprescribers.org.

Members of the *Biologics Prescribers Collaborative*

Alliance for Patient Access | American College of Allergy, Asthma & Immunology | American College of Rheumatology
The American Gastroenterological Association | Clinical Neurological Society of America
Coalition of State Rheumatology Organizations | Endocrine Society | Rheumatology Nurses Society